DrugPatentWatch Database Preview
CUVPOSA Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Cuvposa, and what generic alternatives are available?
The generic ingredient in CUVPOSA is glycopyrrolate. There are seventeen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for CUVPOSA
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 62 |
| Patent Applications: | 2,215 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CUVPOSA |
| DailyMed Link: | CUVPOSA at DailyMed |
Pharmacology for CUVPOSA
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
Medical Subject Heading (MeSH) Categories for CUVPOSA
Synonyms for CUVPOSA
| .beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide |
| (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenyl-acetate bromide |
| (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide |
| [(3S)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide |
| 1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide |
| 1-methyl-3-pyrrolidyl alpha-cyclopentylmandelate methobromide |
| 1-methyl-3-pyrrolidyl alpha-phenyl-alpha-cyclopentylglycolate methobromide |
| 1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide |
| 1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate |
| 1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate |
| 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-ium bromide |
| 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium Bromide |
| 3-(2-phenyl-2-cyclopentylglycoloyloxy)-1,1-dimethylpyrrolidinium bromide |
| 3-(erythro-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidiniumbromid |
| 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium bromide |
| 3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate |
| 3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate |
| 3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate |
| 53808-86-9 |
| 596-51-0 |
| AB0010706 |
| AC-23382 |
| AC1L1XX0 |
| AC1LAW54 |
| AC1Q1RGS |
| AD-237 |
| AHR 504 |
| AHR-504 |
| AK163383 |
| AKOS015962136 |
| alpha-cyclopentylmandelic acid ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide |
| AN-46262 |
| Asecryl |
| BC209826 |
| Bromure de glycopyrronium |
| Bromure de glycopyrronium [INN-French] |
| Bromure de ritropirronio |
| Bromure de ritropirronium |
| Bromuro de glicopirronio |
| Bromuro de glicopirronio [INN-Spanish] |
| C19H28BrNO3 |
| C19H28NO3 |
| CAS-596-51-0 |
| CCG-101030 |
| CCG-213543 |
| CHEBI:90972 |
| CHEMBL1201027 |
| CHF-5992 |
| Copyrrolate |
| CPD000469282 |
| CS-1763 |
| Cuvposa (TN) |
| D00540 |
| DSSTox_CID_3109 |
| DSSTox_GSID_23109 |
| DSSTox_RID_76878 |
| DTXSID6023109 |
| EINECS 209-887-0 |
| FT-0626787 |
| G0392 |
| Gastrodyn |
| GLYCOPYRROLATE |
| Glycopyrrolate (USP) |
| Glycopyrrolate [USAN:USP] |
| Glycopyrrolate [USAN] |
| Glycopyrrolate bromide |
| Glycopyrrolate, >=98% (HPLC) |
| Glycopyrrolate, United States Pharmacopeia (USP) Reference Standard |
| GLYCOPYRRONE BROMIDE |
| Glycopyrroni bromidum |
| Glycopyrronii bromidum |
| Glycopyrronii bromidum [INN-Latin] |
| Glycopyrronium |
| glycopyrronium bromide |
| Glycopyrronium bromide (JAN/INN) |
| Glycopyrronium bromide, European Pharmacopoeia (EP) Reference Standard |
| Glycopyrronium for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Glycopyrronium impurity N, European Pharmacopoeia (EP) Reference Standard |
| glycopyrroniumbromide |
| HE066676 |
| HE344621 |
| HE350010 |
| HE357924 |
| HMS1570E14 |
| HMS2051P12 |
| HMS2094A05 |
| HMS2097E14 |
| HMS2235F12 |
| HMS3259P04 |
| HMS3369F10 |
| HMS3393P12 |
| HY-17465 |
| I14-3643 |
| Lonhala Magnair |
| LS-138344 |
| Mandelic acid, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide |
| MFCD00072137 |
| MLS001424112 |
| MLS002222301 |
| MolPort-006-112-011 |
| NC00280 |
| NC00694 |
| NCGC00179456-02 |
| NCGC00179456-04 |
| Nodapton |
| Nodapton|||Robanul|||Robinul|||Tarodyl|||Tarodyn |
| NSC 250836 |
| NSC 251251 |
| NSC 251252 |
| NSC-250836 |
| NSC-251251 |
| NSC-251252 |
| NSC-759238 |
| NSC250836 |
| NSC251251 |
| NSC251252 |
| NSC759238 |
| NVA 237 |
| NVA-237 |
| Pharmakon1600-01505753 |
| PT-001 |
| Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate |
| Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide |
| Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate |
| Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate (8CI) |
| Pyrrolidinium,1-dimethyl-, bromide |
| Pyrrolidinium,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate |
| Ritropirronium bromide |
| Ritropirronium bromide [INN] |
| RL04249 |
| Robinal |
| Robinul |
| Robinul (TN) |
| ROBINUL FORTE |
| s4660 |
| SAM001246629 |
| SAM002589987 |
| SCHEMBL41436 |
| Seebri |
| Seebri Breezhaler |
| Seebri breezhaler (TN) |
| Seebri Neohaler |
| SMR000469282 |
| ST24047338 |
| ST51054976 |
| Tarodyl |
| Tarodyn |
| Tox21_113144 |
| Tox21_113144_1 |
| Tox21_113145 |
| VPNYRYCIDCJBOM-UHFFFAOYSA-M |
| WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E |
US Patents and Regulatory Information for CUVPOSA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz Pharms | CUVPOSA | glycopyrrolate | SOLUTION;ORAL | 022571-001 | Jul 28, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Merz Pharms | CUVPOSA | glycopyrrolate | SOLUTION;ORAL | 022571-001 | Jul 28, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for CUVPOSA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/5 mL | ➤ Subscribe | ➤ Sign Up |
Non-Orange Book US Patents for CUVPOSA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,091,236 | Method for increasing the bioavailability of glycopyrrolate | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
